Innovent (01801.HK) rises 11% on Pfizer $PFE pact worth up to $10.5B
Original: Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion View original →
11% was the Hong Kong move in Innovent Biologics (01801.HK) after Pfizer $PFE agreed to a global oncology collaboration worth up to $10.5B. The transaction clears the $500M Tier-1 threshold and includes 12 early-stage and de novo cancer medicines.
Pfizer's press release puts the upfront payment at $650M and potential development, regulatory, and commercial milestones at up to $9.85B. MarketScreener reported that Innovent shares rallied 11% in Hong Kong, on pace for the company's largest one-day gain in a year.
| Deal item | Figure |
|---|---|
| Total potential value | Up to $10.5B |
| Upfront payment | $650M |
| Potential milestones | Up to $9.85B |
| Programs | 12 cancer medicines |
The market stake is the valuation of China-origin oncology pipelines in global pharma portfolios. The collaboration covers antibody-drug conjugates and multi-specific antibodies, giving Pfizer access to early assets while Innovent receives non-dilutive capital and global development reach. The next checkpoints are regulatory clearance, program selection, and the first clinical milestone disclosures.
Not investment advice. Verify all figures with primary sources before acting.
Related Articles
Delivery Hero confirmed Uber $UBER made an indicative €33/share takeover approach on 23 May. Reuters market data showed $DHER.DE up about 10% on 25 May, with reports pointing to a bid value above €11.5B.
Jardine Matheson agreed to buy 100% of I-MED Radiology Network at an AUD3.4B ($2.4B) enterprise value. The price equals roughly 11.5x projected adjusted EBITDA for the year ending June 2026, with cash and debt funding and 2026 EPS guidance unchanged.
Eli Lilly $LLY moved higher after reports that the company plans nearly $4B of vaccine acquisitions. The planned deals clear the Tier-1 M&A threshold and extend Lilly’s GLP-1 cash flow into infectious-disease assets.
Comments (0)
No comments yet. Be the first to comment!